Chemnitz

• Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH (ENLIGHTEN-Cirrhosis) Recruiting
  2023-510395-31-00 5 2024-10-30 Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Compensat
• NeoAdjuvant study comparing sacituzumab govitecan versus sacituzumab govitecan+pembrolizumab treatment in low-risk, triple-negative early br … Recruiting
  2023-508787-29-00 4 2024-10-10 Triple-negative early breast cancer with low risk for recurrence
• Clinical trial of MK-2870 in combination with pembrolizumab in people who have had surgery to treat triple negative breast cancer Recruiting
  2023-504962-52-00 5 2024-07-10 Triple negative breast cancer.
• MorningLyte: Evaluation of the benefits of the combination of mosunetuzumab plus lenalidomide versus a treatment with anti-CD20 monoclonal a … Recruiting
  2023-505436-35-00 5 2024-06-03 Untreated FLIPI 2-5 Follicular Lymphoma
• Safety and diagnostic performance of uPAR PET imaging in localised, untreated prostate cancer. Recruiting
  2023-507111-35-00 9 2024-06-03 Prostate Cancer
• A study to discover if ZED1227 can improve continued celiac disease symptoms despite a gluten-free diet Recruiting
  2023-506150-21-00 4 2024-05-29 Celiac Disease
• Venetoclax plus azacitidine versus standard intensive chemotherapy for patients with newly diagnosed acute myeloid leukemia (AML) and NPM1 m … Recruiting
  2024-515267-59-00 4 2024-04-07 Acute myeloid leukemia
• A Global Pivotal Placebo-Controlled Study of LY3537982 in Combination with Pembrolizumab and LY3537982 in Combination with Pembrolizumab, Pe … Recruiting
  2023-503412-33-00 5 2024-03-29 Stage IIIB-IIIC or Stage IV KRAS G12C-mutant non-small cell lung cance
• A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) … Recruiting
  2023-504323-25-01 5 2024-03-19 breast cancer
• An international, multicenter, randomised, superiority phase III, open label, 2-arm study to investigate distant metastasis free survival wi … Recruiting
  2022-501453-36-00 5 2024-02-23 Breast cancer
• Iberdomide Manteinance Versus Lenalidomide Manteinance Therapy Following Autologous Stem Cell Transplant in Participants with NDMM Recruiting
  2022-501515-14-00 5 2023-09-29 Newly Diagnosed Multiple Myeloma (NDMM)
• A Phase I/II First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Anti-Tumor Activity of IMA402, a Bispecific T Cell-Engag … Recruiting
  2022-503133-54-00 7 2023-08-09 Solid Tumors
• Age-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line tr … Recruiting
  2024-512320-11-00 5 2023-08-09 Primary diffuse large B-cell lymphoma of the central nervous system (P
• A multicentre, randomized trial in adults with de novo Philadelphia-Chromosome positive acute lymphoblastic leukemia to assess the efficacy … Recruiting
  2024-517966-40-00 4 2023-07-13 Acute lymphoblastic leukemia (ALL), de novo, Ph/BCR::ABL1 positive (Ph
• Combination treatment of Belantamab Mafodotin and Venetoclax in treatment of relapsed and refractory t(11;14) Multiple Myeloma (Phase I/IIa) … Recruiting
  2024-511794-30-00 9 2023-06-28 Multiple Myeloma
• Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active SLE (POETYK SLE-1) Recruiting
  2022-500699-76-00 5 2023-05-18 Active Systemic Lupus Erythematosus (SLE)
• Venetoclax in combination with Ibrutinib and Rituximab or conventional chemotherapy (Bendamustine) and Ibrutinib and Rituximab in patients w … Recruiting
  2022-501808-96-00 4 2023-05-15 Mantle Cell Lymphoma
• A Randomized, Open-label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R-miniCHOP) in Older Adults wi … Recruiting
  2022-501187-18-00 5 2023-04-24 a. Diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS)
• A Phase 2 Study to Evaluate Safety and Efficacy of Teclistamab-,Talquetamab- and JNJ-79635322-based Combination Regimens in Participants wit … Recruiting
  2024-517382-17-00 4 2022-11-30 Newly Diagnosed Multiple Myeloma in patients eligible for stem cell tr
• A study of tucatinib with trastuzumab and mFOLFOX6 versus standard of care treatment in first-line HER2+ metastatic colorectal cancer Recruiting
  2024-514180-25-00 5 2022-11-21 unresectable or metastatic HER2+ colorectal cancer
• MagnetisMM-6: A Phase 3 Study of Elranatamab (PF-06863135) + Daratumumab + Lenalidomide Versus Daratumumab + Bortezomib + Lenalidomide + Dex … Recruiting
  2024-514139-50-00 5 2022-11-14 Multiple myeloma
• CAPTOR-BC: COMPREHENSIVE ANALYSIS OF SPATIAL, TEMPORAL AND MOLECULAR PATTERNS OF RIBOCICLIB EFFICACY AND RESISTANCE IN ADVANCED BREAST CANCE … Recruiting
  2022-500764-35-00 6 2022-10-13 Patients with advanced HER2-negative, hormone receptor positive (HER2n
• Asciminib Roll-over Study Recruiting
  2023-507557-16-00 5 2022-08-31 chronic myelogenous leukemia (CML) or Philadelphia Chromosome positive
• A study to evaluate efficacy and safety of an investigational drug named volixibat in patients with itching caused by primary biliary cholan … Recruiting
  2023-504660-41-00 4 2022-07-11 Cholestatic Pruritus in Patients with Primary Biliary Cholangitis (PBC

Showing 73–96 of 200 trials